NCT06699121View on ClinicalTrials.gov

A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

February 28, 2029

Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
DRUG

LB-P8 low-dose

One capsule QD (1×10\^10 CFU/day) oral administration

DRUG

LB-P8 high-dose

One capsule QD (1×10\^11 CFU/day) oral administration

DRUG

Placebo

One capsule QD oral administration

Trial Locations (4)

55905

Mayo Clinic, Rochester

80045

UCHealth University of Colorado Hospital, Aurora

95817

University of California Davis, Sacramento

98105

Liver institute Northwest, Seattle

Sponsors
All Listed Sponsors
lead

LISCure Biosciences

INDUSTRY